Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Riad Hussein El-Dada sold 3,500 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.35, for a total value of $32,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Greenland Mines Ltd. Common Stock Stock Down 6.9%
GRML traded down $0.54 on Monday, reaching $7.34. The company’s stock had a trading volume of 4,688,070 shares, compared to its average volume of 23,797,332. The company has a market capitalization of $23.32 million, a price-to-earnings ratio of -0.64 and a beta of 6.26. Greenland Mines Ltd. Common Stock has a fifty-two week low of $2.82 and a fifty-two week high of $36.99. The stock has a 50 day moving average of $8.00 and a two-hundred day moving average of $15.04.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last issued its quarterly earnings data on Monday, August 17th. The company reported ($0.03) earnings per share for the quarter.
Hedge Funds Weigh In On Greenland Mines Ltd. Common Stock
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on GRML shares. Weiss Ratings raised shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a report on Saturday, August 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on GRML
Greenland Mines Ltd. Common Stock Company Profile
Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
Featured Articles
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
